Sutro Biopharma Enacts 1-for-10 Reverse Stock Split
Sutro Biopharma Inc. announced a 1-for-10 reverse stock split effective December 3, 2025. Post-split, shares will trade under the symbol 'STRO' with a new CUSIP number. The split reduces outstanding shares from 85.2 million to 8.5 million to meet Nasdaq's minimum bid price requirement. Adjustments will be made to equity awards and share plans.
Sutro Biopharma Inc. has announced a 1-for-10 reverse stock split of its common stock, effective December 3, 2025. Following the split, the company’s shares will begin trading on a post-split basis under the existing symbol “STRO” with a new CUSIP number. The reverse split reduces the number of outstanding shares from approximately 85.2 million to about 8.5 million and is intended to help the company regain compliance with Nasdaq’s minimum bid price requirement. Proportionate adjustments will also be made to equity awards and share plans. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-306786), on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
